Bruker Daltonics and HealthLinx Expand Biomarker Discovery Collaboration
Complete the form below to unlock access to ALL audio articles.
HealthLinx Limited has announced the signing of a joint patent agreement with Bruker Daltonics Inc. to further develop biomarkers that have been discovered under an existing collaboration between the two life science companies.
These biomarkers are candidates for a number of pregnancy complications based on scientific research using Bruker Daltonics’ ClinProt™ platform.
Associate Professor Greg Rice of HealthLinx and Dr. Gongyi Shi from Bruker Daltonics’ Fremont, California, USA applications laboratory discovered the biomarkers as a result of the two companies’ on-going collaboration and, accordingly, both will be recognised as co-inventors.
Under the new agreement, Bruker Daltonics and HealthLinx will file a joint PCT patent application and share costs associated with the patent and development of the biomarkers.
The patent will focus on the use of the biomarkers as a diagnostic test for the detection of “Complications of Pregnancy”.
It is envisaged that the “test” will be a blood test performed at the first antenatal visit and/or subsequently during pregnancy.
The test will seek to diagnose women with a predisposition to a number of complications in pregnancy including pre-eclampsia, pre-term labour, miscarriage and gestational diabetes.
Women will be classified as either having a high risk or a low risk of developing complications of pregnancy, allowing the gynecologist and/or general practitioner to undertake more appropriate management and/or intervention strategies during the pregnancy to improve outcomes for both mother and baby.
Under the agreement, Bruker Daltonics will retain marketing rights for the test in Europe, UK, Africa and South America, while HealthLinx will retain marketing rights in Australia, New Zealand and Asia.
The two companies will jointly market the test in the United States and Canada.
Furthermore, the two companies will work together to complete the Phase II trial for the ClinProt-based test. HealthLinx will retain world-wide exclusivity for any ELISA/Multiplex based test that may be developed in the future.
HealthLinx’ CEO, Mr Nick Gatsios, said, “The two companies have been working together for the past 12 months on obtaining Phase I validation of the biomarkers and we are excited about the opportunity this presents both companies.”
Dr. Gary Kruppa, Vice President of Bruker Daltonics, stated, “This work represents a further validation of our ClinProt platform for the discovery and identification of biomarkers.
We are also excited about the success of this collaboration to date, and the opportunity that the development of these biomarkers presents. ”
